What are the medical management options for aortic stenosis and aortic regurgitation?

Medical Management of Aortic Stenosis and Aortic Regurgitation

Aortic Stenosis: No Medical Therapy Alters Disease Progression

There is no medical therapy that modifies the natural history of aortic stenosis—the only definitive treatment is aortic valve replacement (surgical or transcatheter) when indicated. 1

Surveillance Strategy for Asymptomatic AS

The cornerstone of AS management is serial monitoring with specific intervals based on severity 2:

• Severe AS: Echocardiography every 6-12 months 2
• Moderate AS: Echocardiography every 1-2 years 2
• Mild AS: Echocardiography every 3-5 years 2

Management of Concurrent Conditions in AS Patients

While no medications treat AS itself, managing comorbidities requires careful consideration:

Hypertension Management

• ACE inhibitors or ARBs are first-line agents for blood pressure control in AS patients with hypertension 3
• These provide beneficial effects on left ventricular fibrosis, reduce dyspnea, and improve effort tolerance 3
• Avoid aggressive blood pressure reduction that could compromise coronary perfusion 2

Beta Blockers in AS

• Beta blockers should be avoided unless there is a compelling indication such as heart failure with reduced ejection fraction, post-myocardial infarction status, or significant arrhythmias 3
• When AS coexists with aortic regurgitation, beta blockers are particularly problematic as they prolong diastole and increase regurgitant volume 3

Atrial Fibrillation

• Rate control is essential but must balance avoiding excessive bradycardia 2
• Anticoagulation management follows standard protocols, with careful perioperative bridging when needed 1

Critical Pitfall: Symptom Assessment

The most common error is accepting a patient's self-reported "asymptomatic" status without objective testing. 1 Elderly patients often unconsciously reduce activity levels, masking symptoms 1. When symptom status is unclear:

• Perform exercise stress testing to unmask symptoms 1
• Measure BNP levels (elevated BNP suggests subclinical decompensation) 1
• A positive exercise test effectively reclassifies the patient as symptomatic, making intervention appropriate 1

---

Aortic Regurgitation: Medical Therapy Has a Role

Moderate Aortic Regurgitation

For moderate AR with hypertension, use vasodilators that do not slow heart rate—specifically ACE inhibitors, ARBs, or dihydropyridine calcium channel blockers like amlodipine or nifedipine. 4

Blood Pressure Management

• Target systolic BP <140 mmHg in hypertensive patients 4
• Dihydropyridine calcium channel blockers (amlodipine, nifedipine) and ACE inhibitors are preferred because they reduce afterload without slowing heart rate 4
• Maintaining or slightly increasing heart rate is beneficial—it shortens diastolic time and reduces regurgitant volume per cardiac cycle 4

Medications to Avoid

• Beta blockers are contraindicated (Class IIa recommendation, Level C evidence) as they prolong diastole and increase regurgitant volume 4, 3
• This is a firm contraindication unless there is heart failure with reduced ejection fraction, recent MI, or life-threatening arrhythmias 3

Surveillance for Moderate AR

• Echocardiography every 1-2 years to detect progression 4
• Clinical assessment yearly for symptom development 4
• Increase imaging frequency to every 3-6 months if LV ejection fraction changes or progressive LV dilatation occurs 4

Markers Indicating Progression to Severe AR

Monitor for these echocardiographic findings that signal need for surgical evaluation 4:

• Vena contracta ≥0.6 cm
• Regurgitant volume ≥60 mL/beat
• Effective regurgitant orifice area (EROA) ≥0.3 cm²
• LV dilatation
• Holodiastolic flow reversal in descending aorta
• LV ejection fraction decline below 50-55%

Surgical Considerations for Moderate AR

Surgery is NOT indicated for moderate AR alone. 4 However, consider concurrent valve surgery (Class IIa recommendation) when the patient requires 4:

• Coronary artery bypass grafting (CABG)
• Mitral valve surgery
• Ascending aorta surgery

The decision should account for AR etiology, patient age, disease progression trajectory, and possibility of valve repair 4.

---

Special Consideration: Combined AS and AR

When severe AS coexists with moderate AR, prioritize the aortic stenosis management unless there are compelling indications for beta blockers (heart failure with reduced ejection fraction, recent MI, life-threatening arrhythmias) 3. In the absence of these indications:

• Use ACE inhibitors or ARBs as first-line antihypertensives 3
• Avoid beta blockers due to the AR component 3
• Mandatory cardiology consultation is recommended for hypertension management in this complex scenario to balance competing hemodynamic concerns 3

---

Low-Flow Low-Gradient AS: A Diagnostic Challenge

When AS appears severe by valve area but gradients are low, distinguish true-severe from pseudo-severe AS 1:

Classical LFLG AS (LVEF <50%)

• Perform dobutamine stress echocardiography (DSE) 1
• True-severe AS (valve area remains <1.0 cm² with increased flow) requires valve replacement 1
• Pseudo-severe AS (valve area increases to >1.0 cm² with increased flow) is treated with medical therapy for underlying cardiomyopathy 1

Paradoxical LFLG AS (LVEF ≥50%)

• This represents a distinct phenotype requiring careful evaluation 1
• Projected valve area at normal flow rate provides additional diagnostic information 1

---

Antibiotic Considerations

Fluoroquinolones (including levofloxacin) should be avoided in patients with aortic stenosis unless there is a compelling clinical indication with no reasonable alternative 5. The European Society of Cardiology gives this a Class IIb, Level B recommendation due to increased risk of aortic aneurysm and dissection 5. In patients with pre-existing aortic pathology like AS, even modest relative risk increases become clinically significant 5.